Keros Therapeutics, Inc. (NASDAQ:KROS) Given Average Rating of “Buy” by Analysts

Keros Therapeutics, Inc. (NASDAQ:KROS) has received an average recommendation of “Buy” from the seven analysts that are covering the firm, Marketbeat Ratings reports. Seven analysts have rated the stock with a buy recommendation. The average twelve-month price objective among brokers that have covered the stock in the last year is $86.00.

A number of research analysts have commented on the company. William Blair reaffirmed an “outperform” rating on shares of Keros Therapeutics in a report on Wednesday, February 21st. Piper Sandler reaffirmed an “overweight” rating and set a $105.00 target price on shares of Keros Therapeutics in a report on Wednesday, March 27th. HC Wainwright reaffirmed a “buy” rating and set a $100.00 target price on shares of Keros Therapeutics in a report on Friday, March 1st. Wedbush reaffirmed an “outperform” rating and set a $86.00 target price on shares of Keros Therapeutics in a report on Thursday, February 29th. Finally, Truist Financial reaffirmed a “buy” rating and set a $100.00 target price on shares of Keros Therapeutics in a report on Wednesday, March 13th.

Institutional Trading of Keros Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in KROS. Point72 Hong Kong Ltd bought a new stake in shares of Keros Therapeutics in the 2nd quarter worth approximately $28,000. Almanack Investment Partners LLC. bought a new stake in shares of Keros Therapeutics in the 3rd quarter worth approximately $32,000. Osaic Holdings Inc. bought a new stake in shares of Keros Therapeutics in the 2nd quarter worth approximately $36,000. Tower Research Capital LLC TRC raised its holdings in shares of Keros Therapeutics by 134.6% in the 1st quarter. Tower Research Capital LLC TRC now owns 1,140 shares of the company’s stock worth $48,000 after purchasing an additional 654 shares in the last quarter. Finally, Lazard Asset Management LLC bought a new stake in shares of Keros Therapeutics in the 1st quarter worth approximately $67,000. 71.56% of the stock is currently owned by institutional investors.

Keros Therapeutics Stock Down 0.5 %

Shares of NASDAQ KROS opened at $58.95 on Friday. Keros Therapeutics has a fifty-two week low of $27.02 and a fifty-two week high of $73.00. The business has a 50 day moving average price of $63.72 and a two-hundred day moving average price of $46.81. The firm has a market cap of $2.12 billion, a PE ratio of -11.34 and a beta of 1.26.

Keros Therapeutics (NASDAQ:KROS) last issued its quarterly earnings data on Friday, March 1st. The company reported ($1.34) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.37) by $0.03. The business had revenue of $0.14 million for the quarter. During the same period in the previous year, the business posted ($1.09) EPS. On average, analysts anticipate that Keros Therapeutics will post -5.11 earnings per share for the current year.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.